Q4 2023

Filed Apr 1, 2024 · 10-K · 92 days after period end · 0001213900-24-028690

Q4 2023 · 10-K

derived · Computed from the longer spans the company filed.

Revenue—

Net Income

-$32.57K

derivedno prior Q4 2022 on file

EPS, diluted—Not derived. Share counts vary by quarter.

Operating Cash Flowderived-$56,766—

Same quarter

no prior Q4 2022 on file

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

ended Dec 31, 2023 · filed Apr 1, 2024 · 92 d after period end

Palomino Laboratories Inc. · CIK 1938569 · Engraved from SEC EDGAR